ID

38231

Description

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours; ODM derived from: https://clinicaltrials.gov/show/NCT01493336

Lien

https://clinicaltrials.gov/show/NCT01493336

Mots-clés

  1. 30/09/2019 30/09/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

30 septembre 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients,>/= 18 years of age
Description

Adult | Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
histological/cytological confirmation of colorectal or breast cancer
Description

Colorectal Carcinoma | Breast Carcinoma

Type de données

boolean

Alias
UMLS CUI [1]
C0009402
UMLS CUI [2]
C0678222
patient is ambulatory and has a karnofsky performance status of > 70%
Description

Patient Ambulatory | Karnofsky Performance Status

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C0439841
UMLS CUI [2]
C0206065
body surface area between 1.5 and 2.0 m2
Description

Body Surface Area

Type de données

boolean

Alias
UMLS CUI [1]
C0005902
either:
Description

Either

Type de données

boolean

Alias
UMLS CUI [1]
C3844638
due to receive xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or
Description

Etiology | Xeloda | Combined Modality Therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0015127
UMLS CUI [2]
C0724419
UMLS CUI [3]
C0009429
currently receiving xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on day 1 and day 2
Description

Xeloda | Ability Receive Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0724419
UMLS CUI [2,1]
C0085732
UMLS CUI [2,2]
C1514756
UMLS CUI [2,3]
C0013230
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any contraindication to xeloda
Description

Medical contraindication Xeloda

Type de données

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0724419
received xeloda in the 6 days prior to day 1
Description

Xeloda Received Recently

Type de données

boolean

Alias
UMLS CUI [1,1]
C0724419
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C0332185
subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy)
Description

Organ allografts | Exception Autologous bone marrow transplant Post High-dose chemotherapy

Type de données

boolean

Alias
UMLS CUI [1,1]
C0178784
UMLS CUI [1,2]
C0040739
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0194037
UMLS CUI [2,3]
C0687676
UMLS CUI [2,4]
C1328050
renal impairment
Description

Renal Insufficiency

Type de données

boolean

Alias
UMLS CUI [1]
C1565489
pregnant or lactating females
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
participation in an investigational drug study within 28 days prior to screening
Description

Study Subject Participation Status | Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome
Description

Lacking Integrity Upper Gastrointestinal Tract | Malabsorption Syndrome

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332268
UMLS CUI [1,2]
C1947912
UMLS CUI [1,3]
C3203348
UMLS CUI [2]
C0024523
serious uncontrolled intercurrent infections
Description

Communicable Diseases Serious Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0205318
history of clinically significant coronary artery disease
Description

Coronary Artery Disease

Type de données

boolean

Alias
UMLS CUI [1]
C1956346
concomitant treatment with warfarin
Description

Warfarin therapy

Type de données

boolean

Alias
UMLS CUI [1]
C4303340
known dihydropyrimidine dehydrogenase deficiency
Description

Dihydropyrimidine Dehydrogenase Deficiency

Type de données

boolean

Alias
UMLS CUI [1]
C1959620

Similar models

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adult patients,>/= 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Colorectal Carcinoma | Breast Carcinoma
Item
histological/cytological confirmation of colorectal or breast cancer
boolean
C0009402 (UMLS CUI [1])
C0678222 (UMLS CUI [2])
Patient Ambulatory | Karnofsky Performance Status
Item
patient is ambulatory and has a karnofsky performance status of > 70%
boolean
C0030705 (UMLS CUI [1,1])
C0439841 (UMLS CUI [1,2])
C0206065 (UMLS CUI [2])
Body Surface Area
Item
body surface area between 1.5 and 2.0 m2
boolean
C0005902 (UMLS CUI [1])
Either
Item
either:
boolean
C3844638 (UMLS CUI [1])
Etiology | Xeloda | Combined Modality Therapy
Item
due to receive xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or
boolean
C0015127 (UMLS CUI [1])
C0724419 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Xeloda | Ability Receive Investigational New Drugs
Item
currently receiving xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on day 1 and day 2
boolean
C0724419 (UMLS CUI [1])
C0085732 (UMLS CUI [2,1])
C1514756 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Xeloda
Item
any contraindication to xeloda
boolean
C1301624 (UMLS CUI [1,1])
C0724419 (UMLS CUI [1,2])
Xeloda Received Recently
Item
received xeloda in the 6 days prior to day 1
boolean
C0724419 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
Organ allografts | Exception Autologous bone marrow transplant Post High-dose chemotherapy
Item
subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy)
boolean
C0178784 (UMLS CUI [1,1])
C0040739 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0194037 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1328050 (UMLS CUI [2,4])
Renal Insufficiency
Item
renal impairment
boolean
C1565489 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs
Item
participation in an investigational drug study within 28 days prior to screening
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Lacking Integrity Upper Gastrointestinal Tract | Malabsorption Syndrome
Item
lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome
boolean
C0332268 (UMLS CUI [1,1])
C1947912 (UMLS CUI [1,2])
C3203348 (UMLS CUI [1,3])
C0024523 (UMLS CUI [2])
Communicable Diseases Serious Uncontrolled
Item
serious uncontrolled intercurrent infections
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
Coronary Artery Disease
Item
history of clinically significant coronary artery disease
boolean
C1956346 (UMLS CUI [1])
Warfarin therapy
Item
concomitant treatment with warfarin
boolean
C4303340 (UMLS CUI [1])
Dihydropyrimidine Dehydrogenase Deficiency
Item
known dihydropyrimidine dehydrogenase deficiency
boolean
C1959620 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial